Axsome Therapeutics (AXSM) announced on Wednesday that the U.S. FDA has granted priority review for its marketing application ...

Axsome stock jumped Wednesday after the biotech firm said its Alzheimer's disease agitation drug will get a priority review.

FDA grants priority review to Axsome's AXS-05 for treating agitation in Alzheimer's disease with a PDUFA date of April 30, 2026.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

Agitation is the third most common neuropsychiatric symptom observed in patients with dementia, with 30% of patients exhibiting these symptoms; the frequency increases to 80% among patients living in ...

Alzheimer’s disease is a form of dementia. Although there are different types of dementia, Alzheimer’s often affects more people than any other. According to the Centers for Disease Control and ...

Agitation can be one of the most troubling symptoms of Alzheimer’s disease. You’ve probably tried everything you could think of to bring calm to your loved one. Keep in mind the behavior is part of ...

Psychomotor agitation typically involves reptitive movements, like toe tapping or fidgeting, and racing thoughts. Psychomotor agitation is a symptom related to a wide range of mood disorders. People ...

psychologist Agitation is a "common and important clinical management problem" in both major psychotic and mood disorders. Agitation is a “common and important clinical management problem” in both ...

This page lists all known medications that could potentially lead to 'Agitation' as a side effect. It's important to note that mild side effects are quite common with medications. The medication(s) ...